The trial BGBC020 shows that Bemcentinib has the potential to increase the rate of ventilator free survival in more than 50% of hospitalised COVID-19 patients, addressing the greatest challenge faced by hospitals worldwide fighting the pandemic.
Ventilator Free Survival observed in 90% in bemcentinib treated patients vs 72% in SOC treated patients, in a subgroup of patients with increased disease severity
Survival benefit numerically greater in bemcentinib treated patients
Bemcentinib anti-viral mechanism of action supported by analysis
Bemcentinib was well tolerated throughout
BerGenBio continues discussions with international governments and regulators about next steps
BerGenBio will be hosting a webcast at 10.00 CEST today (see details below)
PR Newswire
BERGEN, Norway, May 18, 2021